Cancer Genetics

Health genetics medical diagnostics oncology

Cancer Genetics, Inc. (CGI) provides DNA-based cancer diagnostics and services to medical institutions. The Company's tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services. CGI’s tests and reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. The Company's reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited.

Revenue(FY, 2016)

$27 M

Market capitalization(2018-04-20)

$22.8 M

Type

Public

Rutherford, US

Founded

1999

Size (employees)

142 (est)

Website

cancergenetics.com

Cancer Genetics was founded in 1999 and is headquartered in Rutherford, US

Report incorrect company information

Key People/Management at Cancer Genetics

Jay Roberts

Interim Chief Executive Officer & COO

Report incorrect company information

Cancer Genetics Office Locations

Cancer Genetics has offices in Hyderabad, Rutherford, Morrisville, Los Angeles and in 1 other location

Rutherford, US (HQ)

Complex 201 Route 17 North

Los Angeles, US

Health Research Association 1640 Marengo St

Morrisville, US

133 Southcenter Ct

Shanghai, CN

Zhong Guo Yi Dong （ Cai Lun Lu ）

Show all (5)

Report incorrect company information

Cancer Genetics Financials and Metrics

Cancer Genetics Financials

Cancer Genetics's revenue was reported to be $27.05 m in FY, 2016 which is a 49.9% increase from the previous period.

Summary

USD
Revenue (Q2, 2017)	6.6 m
Gross profit (Q2, 2017)	2.6 m
Gross profit margin (Q2, 2017), %	38.9%
EBIT (Q2, 2017)	(3.1 m)
Market capitalization (20-Apr-2018)	22.8 m
Cash (30-Jun-2017)	6.2 m
EV	18.6 m

Cancer Genetics's current market capitalization is $22.8 m.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Revenue	6.6 m	10.2 m	18 m	27 m
Revenue growth, %		54%	77%	50%
Cost of goods sold	4.9 m	8.5 m	14.1 m	17.1 m
Gross profit	1.7 m	1.7 m	3.9 m	9.9 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Revenue	1.7 m	1.4 m	1.5 m	3.2 m	4.4 m	4.2 m	4 m	6.1 m	7 m	6.8 b	7 m	6.6 m
Cost of goods sold	1.2 m	1.3 m	1.5 m	2.6 m	3.1 m	3.1 m	3.1 m	4.1 m	4.3 m	4.4 b	4.2 m	4 m
Gross profit	493.8 k	140.3 k	8.6 k	656.1 k	1.2 m	1.1 m	897.1 k	2 m	2.7 m	2.3 b	2.8 m	2.6 m
Gross profit Margin, %	29%	10%	1%	20%	28%	26%	22%	32%	39%	34%	40%	39%

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	49.5 m	25.6 m	19.5 m	9.5 m
Current Assets	51.9 m	31.8 m	28.2 m	23.4 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Cash	9.9 m	41.3 m	23.7 m	19.9 m	13.3 m	10.6 m	10.7 m	9.7 m	6.2 m
Current Assets	12.2 m	44.1 m	31.1 m	3.8 m	23.5 m	24.5 m	26.6 m	24.4 m	21.9 m
PP&E	810.4 k	1.3 m	3.9 m		5.9 m	5.4 m	4.9 m	4.8 m	4.7 m
Goodwill			3.2 m	3.2 m	12 m	12 m	12 m	12 m	12 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Net Income	(12.4 m)	(16.6 m)	(20.2 m)	(15.8 m)
Depreciation and Amortization	311.2 k	810.2 k	1.5 m	2 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Net Income		(2.5 m)	(6.7 m)
Depreciation and Amortization	227.4 k	96.8 k	214.5 k	487.7 k	347.7 k	679.6 k	971.2 k	518 k	1 m	1.5 m	534 k	981 k
Purchases of PP&E	(72.8 k)	(144 k)	(385.2 k)	(944.4 k)	(83.1 k)	(257.5 k)	(439.7 k)	(319 k)	(319 k)	(345 k)	(178 k)	(400 k)
Cash From Investing Activities	(175.6 k)	(6.2 m)	(6.4 m)	(10.9 m)	(123.2 k)	5.7 m	4.6 m	(358 k)	(405 k)	(472 k)	(209 k)	(663 k)